Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
J Neurosci ; 29(45): 14271-86, 2009 Nov 11.
Article in English | MEDLINE | ID: mdl-19906975

ABSTRACT

M(1) muscarinic acetylcholine receptors (mAChRs) may represent a viable target for treatment of disorders involving impaired cognitive function. However, a major limitation to testing this hypothesis has been a lack of highly selective ligands for individual mAChR subtypes. We now report the rigorous molecular characterization of a novel compound, benzylquinolone carboxylic acid (BQCA), which acts as a potent, highly selective positive allosteric modulator (PAM) of the rat M(1) receptor. This compound does not directly activate the receptor, but acts at an allosteric site to increase functional responses to orthosteric agonists. Radioligand binding studies revealed that BQCA increases M(1) receptor affinity for acetylcholine. We found that activation of the M(1) receptor by BQCA induces a robust inward current and increases spontaneous EPSCs in medial prefrontal cortex (mPFC) pyramidal cells, effects which are absent in acute slices from M(1) receptor knock-out mice. Furthermore, to determine the effect of BQCA on intact and functioning brain circuits, multiple single-unit recordings were obtained from the mPFC of rats that showed BQCA increases firing of mPFC pyramidal cells in vivo. BQCA also restored discrimination reversal learning in a transgenic mouse model of Alzheimer's disease and was found to regulate non-amyloidogenic APP processing in vitro, suggesting that M(1) receptor PAMs have the potential to provide both symptomatic and disease modifying effects in Alzheimer's disease patients. Together, these studies provide compelling evidence that M(1) receptor activation induces a dramatic excitation of PFC neurons and suggest that selectively activating the M(1) mAChR subtype may ameliorate impairments in cognitive function.


Subject(s)
Carboxylic Acids/pharmacology , Cholinergic Agents/pharmacology , Learning Disabilities/drug therapy , Neurons/drug effects , Prefrontal Cortex/drug effects , Quinolones/pharmacology , Reversal Learning/drug effects , Animals , CHO Cells , Cricetinae , Cricetulus , Female , Humans , In Vitro Techniques , Learning Disabilities/physiopathology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Neurons/physiology , Prefrontal Cortex/physiology , Prefrontal Cortex/physiopathology , Rats , Rats, Sprague-Dawley , Receptor, Muscarinic M1/metabolism , Reversal Learning/physiology
2.
Neurobiol Aging ; 28(4): 619-26, 2007 Apr.
Article in English | MEDLINE | ID: mdl-16600436

ABSTRACT

The present study examined muscarinic receptor/G-protein coupling in the hippocampus and the prefrontal cortex of young and aged Long-Evans rats characterized for spatial learning ability in the Morris water maze. In a highly sensitive time-resolved fluorometry GTP-Eu binding assay, muscarinic-mediated GTP-Eu binding was severely blunted in hippocampus (-32%) and prefrontal cortex (-34%) as a consequence of aging. Furthermore, the magnitude of decreased muscarinic-mediated GTP-Eu binding was significantly correlated with the severity of spatial learning impairment in hippocampus and prefrontal cortex of aged rats and was specifically decreased in the subset of aged rats that were spatial learning impaired when compared to the aged unimpaired and the young rats. Western blot data indicated a preservation of the membrane-bound M1 receptor and the Galphaq/11 protein in both brain regions. These data demonstrate that muscarinic signaling is severely impaired as a consequence of normal aging in a manner that is closely associated with age-related cognitive decline.


Subject(s)
Aging/physiology , Guanosine Triphosphate/metabolism , Hippocampus/metabolism , Memory Disorders , Prefrontal Cortex/metabolism , Receptors, Muscarinic/physiology , Space Perception/physiology , Age Factors , Analysis of Variance , Animals , Behavior, Animal , Cell Membrane/metabolism , Dose-Response Relationship, Drug , Hippocampus/drug effects , Male , Maze Learning/physiology , Memory Disorders/metabolism , Memory Disorders/pathology , Memory Disorders/physiopathology , Muscarinic Agonists/pharmacology , Oxotremorine/analogs & derivatives , Oxotremorine/pharmacology , Prefrontal Cortex/drug effects , Protein Binding/drug effects , Rats , Rats, Long-Evans
SELECTION OF CITATIONS
SEARCH DETAIL